- Oops!Something went wrong.Please try again later.
These COVID-19 vaccine developers are all moving in response to strong late-stage results for Valneva's VLA2001.
Admittedly, I don't have many stocks in my portfolio that pay high dividend yields. My positions tend to focus more on growth than on dividends. AbbVie (NYSE: ABBV) is only one dividend increase away from becoming a Dividend King -- S&P 500 members with at least 50 consecutive years of dividend increases.
In this article, we discuss Cathie Wood’s top 15 small-cap stock picks. If you want to skip our detailed analysis of Wood’s history, investment philosophy, and hedge fund performance, go directly to Cathie Wood’s Top 5 Small-Cap Stock Picks. Catherine Wood is an American millionaire investor, who founded ARK Investment Management in 2014. She serves […]
In this article, we discuss the 9 best hydrogen fuel cell stocks to buy. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Hydrogen Fuel Cell Stocks To Buy. Hydrogen fuel cell technology is set to grow as governments around the world get serious about solving the climate […]
R "Ray" Wang, Constellation Research Principal Analyst & Founder, joins Yahoo Finance to discuss the latest product releases from Apple ahead of the holiday season.
Shares of the biotech companies are slumping after the failure of a trial for its treatment for amyotrophic lateral sclerosis.
When it comes down to it, the greatest threat to your comfort in retirement is you.
Coal stock Peabody Energy (NYSE: BTU) shot up Monday morning, having jumped as much as 20.6% as of 11:10 a.m. EDT after the market took a liking to the coal producer's preliminary numbers. A deeper dive into the numbers, though, reflects muted year-over-year growth, which means there was more to Peabody Energy stock's rally this morning. The biggest number from Peabody Energy's preliminary results that caught the market's attention is its coal sales, which crossed $900 million during the quarter to levels last seen nearly seven quarters ago.
Bad news the company received today from the FDA surprised investors more than it probably should have.
In this article, we discuss the top 10 dividend stock picks of billionaire Ken Fisher. If you want to skip our detailed analysis of these stocks, go directly to Billionaire Ken Fisher’s Top 5 Dividend Stock Picks. Ken Fisher is one of the most well-known hedge fund managers on Wall Street. The portfolio of his […]
These companies give investors diverse exposure to the EV sector with the potential for long-term rewards.
BlackBerry (NYSE: BB) and Nokia (NYSE: NOK) both rose from the ashes over the past decade. BlackBerry expanded its enterprise software business, discontinued its first-party smartphone business five years ago, then licensed its brand to third-party smartphone makers. Nokia sold its handset division to Microsoft in 2014, bought its rival Alcatel-Lucent in 2016 to expand its core telecommunications equipment business, and started to license its brand out to other smartphone makers that same year.
Facebook has posted an unusual thread to its Twitter account, suggesting that major revelations are on their way. The thread, and its attack on unnamed journalists, came after weeks of reports about the internal workings of Facebook. Relying on internal documents, reports suggested that Facebook was for instance aware of the damage its platforms were doing to young women.
Shares of MannKind (NASDAQ: MNKD), a company working to develop inhaled therapeutics, were down 18% as of 11:59 a.m. EDT on Monday after an inspection issue derailed its hopes of approval for Tyvaso DPI, a lung disease therapy it developed with United Therapeutics (NASDAQ: UTHR). According to United Therapeutics' Securities and Exchange Commission filings, it owns two patents for treating PAH through inhalation that expire in 2024. The Food and Drug Administration's complete response letter didn't cite issues with MannKind's operations or even the clinical data submitted by the two companies.
Traders could go long FCX ahead of earnings on Thursday.
General Electric's (NYSE: GE) upcoming earnings report is unlikely to produce any significant surprises on a headline basis. After all, management tends to give wide guidance ranges, and CEO Larry Culp spoke extensively about trading conditions at a conference in mid-September. Investors will be very interested in putting the pieces together to build a picture for 2022 and beyond.
The FDA rejected Revance Therapeutics' frown lines treatment, depressing RVNC stock which fell to an 18-month low on Monday.
FuelCell Energy Inc (NASDAQ: FCEL) is surging on abnormally high volume Monday as retail investors gravitate toward the stock on social media platforms. FuelCell's average session volume is about 23 million over a 100-day period. Monday's session volume had already exceeded 80 million at publication time. FuelCell's total float is 366.478 million shares, according to data from Benzinga Pro. Retail investors in the "FinTwit" community are circling the stock for a potential technical breakout. "Fi
Yahoo Finance's Jennifer Schonberger breaks down what to know about the Bitcoin futures ETF set to trade on the NYSE.
Every investor in fuboTV Inc. ( NYSE:FUBO ) should be aware of the most powerful shareholder groups. Generally...